Neuronal function
... B) Myelin: saltatory conduction for fast signals 3. Synapses: Communication between neurons A)electrical synapses B) chemical synapses 4. Post-synaptic potentials A) EPSP & IPSP B) Neuronal decisions via summation C) Ionic vs metabolic synapses 5. Presynaptic potentials A) Autoreceptors and pre-syna ...
... B) Myelin: saltatory conduction for fast signals 3. Synapses: Communication between neurons A)electrical synapses B) chemical synapses 4. Post-synaptic potentials A) EPSP & IPSP B) Neuronal decisions via summation C) Ionic vs metabolic synapses 5. Presynaptic potentials A) Autoreceptors and pre-syna ...
Introduction to Pharmacology
... alters the structure or function of biological systems (pharmacologist’s view). – Any agent approved by the Food and Drug Administration for the treatment or prevention of disease (legal view). – Any agent taken by some, but disapproved by others (societal view). ...
... alters the structure or function of biological systems (pharmacologist’s view). – Any agent approved by the Food and Drug Administration for the treatment or prevention of disease (legal view). – Any agent taken by some, but disapproved by others (societal view). ...
Possible Test Questions
... Common Neurotransmitter Receptors found in Psych. Drugs and their effects - SERT – Serotonin Transporter – Serotoin Reuptake Inhibitors (SRI’s or SSRI’s) – i.e. some drugs, particularly the SSRIs, blockade (antagonize) the SERT leading to ↓ reuptake of serotonin back into the presynaptic neurons a ...
... Common Neurotransmitter Receptors found in Psych. Drugs and their effects - SERT – Serotonin Transporter – Serotoin Reuptake Inhibitors (SRI’s or SSRI’s) – i.e. some drugs, particularly the SSRIs, blockade (antagonize) the SERT leading to ↓ reuptake of serotonin back into the presynaptic neurons a ...
Pellow, S., File, S.E. (1986). Anxiolytic and anxiogenic drug effects
... anxiogenic compounds. The present study investigated the effects of intraperitoneal (i.p) injection of cannabinoid CB1 receptor antagonist (AM251) in the presence of alpha-1 adrenergic antagonist (Prazosin) on rat behavior in the EPM. Materials and Methods: In the present study, the data were obtain ...
... anxiogenic compounds. The present study investigated the effects of intraperitoneal (i.p) injection of cannabinoid CB1 receptor antagonist (AM251) in the presence of alpha-1 adrenergic antagonist (Prazosin) on rat behavior in the EPM. Materials and Methods: In the present study, the data were obtain ...
outside the cell
... Bi 1 Cameo by Professor Pamela J. Bjorkman http://www.search.caltech.edu/CIT_People/action.lasso?-database=CIT_People&response=Detail_Person.html&-layout=all_fields&person_id=29067&-search ...
... Bi 1 Cameo by Professor Pamela J. Bjorkman http://www.search.caltech.edu/CIT_People/action.lasso?-database=CIT_People&response=Detail_Person.html&-layout=all_fields&person_id=29067&-search ...
Steps in synaptic transmission.
... Type (or types) of receptor through which the drug acts (alpha1, alpha2, beta1, etc) Normal response to activation of those receptors (agonist versus antagonist) What the drug in question does to receptor function ...
... Type (or types) of receptor through which the drug acts (alpha1, alpha2, beta1, etc) Normal response to activation of those receptors (agonist versus antagonist) What the drug in question does to receptor function ...
PowerPoint - Pitt Honors Human Physiology
... • These drugs are fairly selective for PDE5, but there are limited actions on other enzymes. For example, Sildenafil is only about 10-fold as potent for PDE5 compared to PDE6, an enzyme found in the retina; this cross reactivity is thought to be the basis for abnormalities related to color vision o ...
... • These drugs are fairly selective for PDE5, but there are limited actions on other enzymes. For example, Sildenafil is only about 10-fold as potent for PDE5 compared to PDE6, an enzyme found in the retina; this cross reactivity is thought to be the basis for abnormalities related to color vision o ...
مهم
... These drugs are used as antihypertensive drugs. Therapeutic uses of Beta 1 activation: 1.Cardiac arrest activate cardiac B1 receptor initiate beat in heart that stopped ...
... These drugs are used as antihypertensive drugs. Therapeutic uses of Beta 1 activation: 1.Cardiac arrest activate cardiac B1 receptor initiate beat in heart that stopped ...
![6]Hydrophobic Interactions](http://s1.studyres.com/store/data/003841520_1-afb7faacf28cd9a1e09bdad5899738ba-300x300.png)
6]Hydrophobic Interactions
... •So, the requirements for the ACE inhibitor drug is : (1) Contain anionic site [COO-] (2) Contain H-bond forming group [C=O] (3) Contain SH, COO- or phosphinate group to react with Zn++. (4) Contain hydrophobic moiety [if methyl as in captopril S isomer is more active > R] ...
... •So, the requirements for the ACE inhibitor drug is : (1) Contain anionic site [COO-] (2) Contain H-bond forming group [C=O] (3) Contain SH, COO- or phosphinate group to react with Zn++. (4) Contain hydrophobic moiety [if methyl as in captopril S isomer is more active > R] ...
Autonomní nervový systém
... Guanethidine • peripheral acting sympatolytics (causes hypotensive states, especially in the morning) • Blocks exocytosis – release of NE • Local miotic agent ...
... Guanethidine • peripheral acting sympatolytics (causes hypotensive states, especially in the morning) • Blocks exocytosis – release of NE • Local miotic agent ...
1. Neurotransmitter released from the pre
... 13. Ways by which the effects on the postsynaptic cell can be enhanced are: a. Presynaptic facilitation b. High frequency of action potentials in the presynaptic terminal c. Adding an agonist for the receptors on the postsynaptic cell d. Blocking the reuptake of NT into the presynaptic terminal e. ...
... 13. Ways by which the effects on the postsynaptic cell can be enhanced are: a. Presynaptic facilitation b. High frequency of action potentials in the presynaptic terminal c. Adding an agonist for the receptors on the postsynaptic cell d. Blocking the reuptake of NT into the presynaptic terminal e. ...
EVALUATION OF ANTIHYPERLIPIDEMIC AND ANTIATHEROSCLEROTIC POTENTIAL OF RIMONABANT IN EXPERIMENTAL ANIMALS
... for 30 days. Estimation of the serum lipid profile in rats receiving high fat diet revealed rise in the levels of serum cholesterol and triglyceride, LDLC, VLDL-C, Atherogenic index (p<0.01) as compared to control, and decrease in HDL-C (p<0.05). Whereas Rimonabant treated groups with high fat diet ...
... for 30 days. Estimation of the serum lipid profile in rats receiving high fat diet revealed rise in the levels of serum cholesterol and triglyceride, LDLC, VLDL-C, Atherogenic index (p<0.01) as compared to control, and decrease in HDL-C (p<0.05). Whereas Rimonabant treated groups with high fat diet ...
No Slide Title
... • Activation of SXR may predict effects of suspected EDC – SXR activators may be detoxified by CYP action and not a human risk – But activators may also be toxified by CYP action, increasing the risk. – EDC may have no effect on SXR and therefore more likely to act on other receptors, e.g. ER ...
... • Activation of SXR may predict effects of suspected EDC – SXR activators may be detoxified by CYP action and not a human risk – But activators may also be toxified by CYP action, increasing the risk. – EDC may have no effect on SXR and therefore more likely to act on other receptors, e.g. ER ...
No Slide Title - Bruce Blumberg
... • Activation of SXR may predict effects of suspected EDC – SXR activators may be detoxified by CYP action and not a human risk – But activators may also be toxified by CYP action, increasing the risk. – EDC may have no effect on SXR and therefore more likely to act on other receptors, e.g. ER ...
... • Activation of SXR may predict effects of suspected EDC – SXR activators may be detoxified by CYP action and not a human risk – But activators may also be toxified by CYP action, increasing the risk. – EDC may have no effect on SXR and therefore more likely to act on other receptors, e.g. ER ...
Drug - respiratorytherapyfiles.net
... Some drugs are made up of several elements combined to make the drug which has no charge (neither plus or minus). If these drugs can be ionized, they can split into two parts. One of the parts carries a plus charge (+) while the other part has a negative charge (-). A simple example is table salt or ...
... Some drugs are made up of several elements combined to make the drug which has no charge (neither plus or minus). If these drugs can be ionized, they can split into two parts. One of the parts carries a plus charge (+) while the other part has a negative charge (-). A simple example is table salt or ...
Lexapro Information
... 4. Stereochemical designations: s/r-mirror images; d/l-rotate a plane of polarized light in opposite directions. 5. As most receptors can distinguish between stereoisomers, they can have different biologic activity. Examples include R-carvone vs. S-carvone(spearmint, caraway), Darvon vs. Novrad, and ...
... 4. Stereochemical designations: s/r-mirror images; d/l-rotate a plane of polarized light in opposite directions. 5. As most receptors can distinguish between stereoisomers, they can have different biologic activity. Examples include R-carvone vs. S-carvone(spearmint, caraway), Darvon vs. Novrad, and ...
Medicinal Chemistry (MDCH) 5220
... (6) What are agonists, antagonists and inverse agonists of the benzodiazepine receptor? Parkinsons (1) What is Parkinsons disease and how can we treat it? (2) Why is dopamine a poor drug for treating Parkinsons? (3) What are various hypotheses as to the cause of Parkinsons? (4) Learn about the major ...
... (6) What are agonists, antagonists and inverse agonists of the benzodiazepine receptor? Parkinsons (1) What is Parkinsons disease and how can we treat it? (2) Why is dopamine a poor drug for treating Parkinsons? (3) What are various hypotheses as to the cause of Parkinsons? (4) Learn about the major ...
Drug Abuse or… For Big Kids - Department of Cognitive Science
... – one issue with this type of study is the ambiguity of the cause of reduced dopamine transporters/dopaminergic terminals – did meth abuse cause this difference or was it the result of previously existing factors such as genetics (in which case, did these genetic differences predispose the individua ...
... – one issue with this type of study is the ambiguity of the cause of reduced dopamine transporters/dopaminergic terminals – did meth abuse cause this difference or was it the result of previously existing factors such as genetics (in which case, did these genetic differences predispose the individua ...
PowerPoint
... the receptor but, once attached, has no effect other than to BLOCK the receptor from the drugs that DO cause an effect. Example: Naloxone ...
... the receptor but, once attached, has no effect other than to BLOCK the receptor from the drugs that DO cause an effect. Example: Naloxone ...
Drug Dosage and Clinical Responses
... • Potency refers to the amount of drug necessary to produce a certain effect. A drug which produces a certain effect at 5 mg dosage is ten times more potent than a drug which produces the same effect at 50 mg dosage. • Clinical efficacy (or simply efficacy) refers to the maximal clinical response th ...
... • Potency refers to the amount of drug necessary to produce a certain effect. A drug which produces a certain effect at 5 mg dosage is ten times more potent than a drug which produces the same effect at 50 mg dosage. • Clinical efficacy (or simply efficacy) refers to the maximal clinical response th ...
5-HT receptor - Pharmatutor
... Ketanserin is a 5-HT2A/2C antagonist used for the treatment of hypertension. In addition to its serotonin antagonism, it has affinity for alpha-1 receptors, which may contribute to its antihypertensive effect. Clozapine is an atypical antipsychotic drug that acts as 5-HT2A/2C receptor antagonist wit ...
... Ketanserin is a 5-HT2A/2C antagonist used for the treatment of hypertension. In addition to its serotonin antagonism, it has affinity for alpha-1 receptors, which may contribute to its antihypertensive effect. Clozapine is an atypical antipsychotic drug that acts as 5-HT2A/2C receptor antagonist wit ...
abstract-orderBYpresenter-board-number_DAY1
... NEUROANATOMICAL BACKGROUND OF PESSIMISM: THE ROLE OF PREFRONTAL AND ORBITOFRONTAL CORTICES IN COGNITIVE JUDGMENT BIAS IN RATS ROLE OF BRAIN NEUROTRANSMITTERS IN PARKINSON’S INDUCED RATS IMPAIRED EMOTIONAL BEHAVIOR OF BACHD RATS, A TRANSGENIC MODEL OF HUNTINGTON’S DISEASE EFFECT OF ADOLESCENT Δ9-THC ...
... NEUROANATOMICAL BACKGROUND OF PESSIMISM: THE ROLE OF PREFRONTAL AND ORBITOFRONTAL CORTICES IN COGNITIVE JUDGMENT BIAS IN RATS ROLE OF BRAIN NEUROTRANSMITTERS IN PARKINSON’S INDUCED RATS IMPAIRED EMOTIONAL BEHAVIOR OF BACHD RATS, A TRANSGENIC MODEL OF HUNTINGTON’S DISEASE EFFECT OF ADOLESCENT Δ9-THC ...
Cannabinoid receptor antagonist
The discovery of the endogenous cannabinoid system led to the development of CB1 receptor antagonists. The first cannabinoid receptor antagonist, rimonabant, was described in 1994. Rimonabant blocks the CB1 receptor selectively and it has been shown to decrease food intake and regulate body-weight gain. The prevalence of obesity worldwide is increasing dramatically and has a great impact on public health. The lack of efficient and well-tolerated drugs to cure obesity has led to an increased interest in research and development of cannabinoid antagonists. Cannabidiol, a naturally occurring cannabinoid, is a non-competitive CB1/2 antagonist.